PAR · SAN.PA
Sanofi
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
Loading market information…
PAR · BOI.PA · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Boiron S.A.’s quoted price sits in the lower half of its reported 52-week range, 42.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Boiron S.A.’s forward annual dividend is €1.35 per share, paid annual. The forward yield is 7.22% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Boiron S.A.’s next earnings report is currently expected on Mar 24, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Boiron S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€76.15+€0.64 (+0.85%)
Sanofi’s quoted price sits in the lower half of its reported 52-week range, 16.13% below the high.
€178.20+€0.50 (+0.28%)
EssilorLuxottica S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.97% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€155.80+€2.90 (+1.9%)
Ipsen S.A.’s quoted price sits in the upper half of its reported 52-week range, 10.46% below the high.
€90.15-€0.85 (-0.93%)
bioMérieux S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
€81.10+€0.35 (+0.43%)
Abivax S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.65% below the high.
€344.50-€3.00 (-0.86%)
Virbac S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.55% below the high.
€10.43+€0.35 (+3.47%)
Emeis’s quoted price sits in the lower half of its reported 52-week range, 34.81% below the high.
